About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
IP: Maria Buti Ferret Collaborators: Jordi Gómez i Prat, Hakima Ouaarab Essadek Funding agency: Gilead Sciences, S.L.U. Funding: 46416 Reference: GLD24/00062 Duration: 27/02/2025 - 30/06/2027
IP: María José Buzón Gómez Collaborators: Adria Curran Fàbregas, Oriol Ruiz Isant Funding agency: Gilead Sciences, S.L.U. Funding: 54999 Reference: GLD24/00014 Duration: 21/02/2025 - 20/02/2027
IP: Jordi Bove Badell Collaborators: Oscar Len Abad, Jordi Mollet Sánchez, Xavier Serres Créixams, Oriol de Fabregues-Boixar Nebot, Maria Piñana Moro Funding agency: Instituto de Salud Carlos III Funding: 221250 Reference: PI24/01820 Duration: 01/01/2025 - 31/12/2027
IP: Meritxell Genesca Ferrer Collaborators: Patricia Álvarez López, Aleix Benítez Martínez Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 231250 Reference: PID2023-149204OB-I00 Duration: 01/09/2024 - 31/12/2027
Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.
The DETECTIVE doctoral network, coordinated by the University of Turku and funded by the Marie Skłodowska-Curie Actions of the Horizon Europe programme, will train 14 predoctoral researchers in five countries.
The initiative focuses on awareness, prevention, and the normalization of sexual health check-ups among young people.
